CELC
Price
$49.96
Change
+$0.50 (+1.01%)
Updated
Aug 27 closing price
Capitalization
2.12B
81 days until earnings call
CLRB
Price
$4.82
Change
+$0.06 (+1.26%)
Updated
Aug 27 closing price
Capitalization
15.19M
Interact to see
Advertisement

CELC vs CLRB

Header iconCELC vs CLRB Comparison
Open Charts CELC vs CLRBBanner chart's image
Celcuity
Price$49.96
Change+$0.50 (+1.01%)
Volume$737.75K
Capitalization2.12B
Cellectar Biosciences
Price$4.82
Change+$0.06 (+1.26%)
Volume$325.08K
Capitalization15.19M
CELC vs CLRB Comparison Chart in %
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. CLRB commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Buy and CLRB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (CELC: $49.96 vs. CLRB: $4.82)
Brand notoriety: CELC and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 28% vs. CLRB: 198%
Market capitalization -- CELC: $2.12B vs. CLRB: $15.19M
CELC [@Biotechnology] is valued at $2.12B. CLRB’s [@Biotechnology] market capitalization is $15.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 1 FA rating(s) are green whileCLRB’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 1 green, 4 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 3 TA indicator(s) are bullish while CLRB’s TA Score has 2 bullish TA indicator(s).

  • CELC’s TA Score: 3 bullish, 6 bearish.
  • CLRB’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, CLRB is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а +2.44% price change this week, while CLRB (@Biotechnology) price change was +9.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.04%. For the same industry, the average monthly price growth was +19.75%, and the average quarterly price growth was +30.54%.

Reported Earning Dates

CELC is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+4.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($2.12B) has a higher market cap than CLRB($15.2M). CELC YTD gains are higher at: 281.665 vs. CLRB (-46.265). CLRB has higher annual earnings (EBITDA): -38.26M vs. CELC (-135.56M). CELC has more cash in the bank: 168M vs. CLRB (11M). CLRB has less debt than CELC: CLRB (454K) vs CELC (99.4M). CELC (0) and CLRB (0) have equivalent revenues.
CELCCLRBCELC / CLRB
Capitalization2.12B15.2M13,947%
EBITDA-135.56M-38.26M354%
Gain YTD281.665-46.265-609%
P/E RatioN/AN/A-
Revenue00-
Total Cash168M11M1,527%
Total Debt99.4M454K21,894%
FUNDAMENTALS RATINGS
CELC vs CLRB: Fundamental Ratings
CELC
CLRB
OUTLOOK RATING
1..100
8773
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
26100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3493
P/E GROWTH RATING
1..100
10075
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (56) in the Biotechnology industry is in the same range as CELC (85) in the Miscellaneous Commercial Services industry. This means that CLRB’s stock grew similarly to CELC’s over the last 12 months.

CELC's Profit vs Risk Rating (26) in the Miscellaneous Commercial Services industry is significantly better than the same rating for CLRB (100) in the Biotechnology industry. This means that CELC’s stock grew significantly faster than CLRB’s over the last 12 months.

CELC's SMR Rating (99) in the Miscellaneous Commercial Services industry is in the same range as CLRB (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's Price Growth Rating (34) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for CLRB (93) in the Biotechnology industry. This means that CELC’s stock grew somewhat faster than CLRB’s over the last 12 months.

CLRB's P/E Growth Rating (75) in the Biotechnology industry is in the same range as CELC (100) in the Miscellaneous Commercial Services industry. This means that CLRB’s stock grew similarly to CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCCLRB
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 6 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VERI3.040.12
+4.11%
Veritone
WBD12.150.35
+2.97%
Warner Bros Discovery
MGNI25.570.43
+1.71%
Magnite
BZH25.390.08
+0.32%
Beazer Homes USA
BCTX7.60-0.61
-7.43%
Briacell Therapeutics Corp NEW

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+1.01%
IMA - CELC
86%
Closely correlated
+0.07%
MRSN - CELC
62%
Loosely correlated
-0.26%
NEVPF - CELC
61%
Loosely correlated
N/A
SLXN - CELC
50%
Loosely correlated
+0.83%
ABOS - CELC
44%
Loosely correlated
-4.79%
More

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been closely correlated with QTTB. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLRB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
+1.26%
QTTB - CLRB
66%
Closely correlated
-5.49%
ADCT - CLRB
42%
Loosely correlated
+1.58%
IBRX - CLRB
40%
Loosely correlated
-1.68%
ANAB - CLRB
39%
Loosely correlated
+2.20%
CELC - CLRB
37%
Loosely correlated
+1.01%
More